Risk factors for mortality among aggressive non-Hodgkin lymphoma patients in Lilongwe, Malawi.

<p>Risk factors for mortality among aggressive non-Hodgkin lymphoma patients in Lilongwe, Malawi.</p

Peripheral blood counts with interquartile ranges during CHOP chemotherapy in Lilongwe, Malawi.

<p>Peripheral blood counts with interquartile ranges during CHOP chemotherapy in Lilongwe, Malawi.</p

Overall survival estimates for aggressive non-Hodgkin lymphoma in Lilongwe, Malawi.

<p>Overall survival estimates for aggressive non-Hodgkin lymphoma in Lilongwe, Malawi.</p

Overall survival for aggressive non-Hodgkin lymphoma in Lilongwe, Malawi.

<p>(A) Overall cohort with 95% confidence intervals. (B) Aggressive B-cell non-Hodgkin lymphoma (ABNHL) versus aggressive T-cell non-Hodgkin lymphoma (ATNHL). (C) Stratified by HIV status. (D) Stratified by international prognostic index (IPI). (E) Diffuse large B-cell lymphoma (DLBCL) stratified by HIV status. (F) DBLCL stratified by IPI.</p

Treatment course and toxicities during CHOP chemotherapy in Lilongwe, Malawi.

<p>Treatment course and toxicities during CHOP chemotherapy in Lilongwe, Malawi.</p

Neutropenia during CHOP chemotherapy in Lilongwe, Malawi.

<p>Neutropenia during CHOP chemotherapy in Lilongwe, Malawi.</p

Baseline characteristics for adults with aggressive non-Hodgkin lymphoma in Lilongwe, Malawi, June 2013 to May 2015.

<p>Baseline characteristics for adults with aggressive non-Hodgkin lymphoma in Lilongwe, Malawi, June 2013 to May 2015.</p